Prosecution Insights
Prosecution Insights
5 pending office actions • 3 art units • 5 examiners • 0 of 5 (0%) have an AI response strategy ready • 14 patents granted in the last 365 days
Based on the USPTO statutory response window for each pending office action. 1 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §102 only | 1 (20%) |
| §112 only | 1 (20%) |
| Multi-statute (no §101) | 3 (60%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| KOSACK, JOSEPH R | 1 | 74.8% | -5.6% |
| SHTERENGARTS, SAMANTHA L | 1 | 79.3% | +8.0% |
| AEDER, SEAN E | 1 | 56.9% | +19.9% |
| TOWNSLEY, SARA ELIZABETH | 1 | 24.9% | +48.9% |
| MOU, LIYUAN | 1 | 43.5% | +57.7% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 3 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 17629910 | DEGRADATION OF BRUTON'S TYROSINE KINASE (BTK) BY CONJUGATION OF BTK INHIBITORS WITH E3 LIGASE LIGAND AND METHODS OF USE | MOU, LIYUAN | 31d overdue |
| 18245654 | Interleukin 15 Constructs and Methods of Use | AEDER, SEAN E | — |
| 18016292 | DEGRADATION OF (EGFR) BY CONJUGATION OF EGFR INHIBITORS WITH E3 LIGASE LIGAND AND METHODS OF USE | TOWNSLEY, SARA ELIZABETH | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 3 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 17629910 | DEGRADATION OF BRUTON'S TYROSINE KINASE (BTK) BY CONJUGATION OF BTK INHIBITORS WITH E3 LIGASE LIGAND AND METHODS OF USE | MOU, LIYUAN | 31d overdue |
| 18245654 | Interleukin 15 Constructs and Methods of Use | AEDER, SEAN E | — |
| 18016292 | DEGRADATION OF (EGFR) BY CONJUGATION OF EGFR INHIBITORS WITH E3 LIGASE LIGAND AND METHODS OF USE | TOWNSLEY, SARA ELIZABETH | — |
| Art Unit | Apps |
|---|---|
| 1642 | 1 |
| 1629 | 1 |
| 1628 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18926544 | Substituted 7-(Pyrimidin-4-yl)Quinolin-4(1H)-One Compounds as Cyclin Dependent Kinase Inhibitors | KOSACK, JOSEPH R | — | §102 | Non-Final OA | — | Pending | Oct 25, 2024 |
| 18825776 | 4-(Aminomethyl)-6-(1-Methyl-1H-Pyrazol-4-YL)Isoquinolin-1(2H)-One Derivatives as MTA-Cooperative Inhibitors of PRMT5 | SHTERENGARTS, SAMANTHA L | — | §112 | Non-Final OA | — | Pending | Sep 05, 2024 |
| 18245654 | Interleukin 15 Constructs and Methods of Use | AEDER, SEAN E | 1642 | §102§103§112 | Non-Final OA | — | Pending | Mar 16, 2023 |
| 18016292 | DEGRADATION OF (EGFR) BY CONJUGATION OF EGFR INHIBITORS WITH E3 LIGASE LIGAND AND METHODS OF USE | TOWNSLEY, SARA ELIZABETH | 1629 | §102§103§112 | Final Rejection | — | Pending | Jan 13, 2023 |
| 17629910 | DEGRADATION OF BRUTON'S TYROSINE KINASE (BTK) BY CONJUGATION OF BTK INHIBITORS WITH E3 LIGASE LIGAND AND METHODS OF USE | MOU, LIYUAN | 1628 | §103§112 | Non-Final OA | 31d overdue | Pending | Jan 25, 2022 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial